Diasorin SpA (MIL:DIA) Tax Provision : €-51 Mil (TTM As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA Tax Provision?

Diasorin SpA's tax provision for the three months ended in Jun. 2024 was €-15 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was €-51 Mil.

Diasorin SpA Tax Provision Historical Data

The historical data trend for Diasorin SpA's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Tax Provision Chart

Diasorin SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-40.55

-73.08

-88.60

-85.83

-42.71

Diasorin SpA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Tax Provision	Get a 7-Day Free Trial															-7.00	-9.71	-14.00	-15.00	-12.00

Diasorin SpA Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51 Mil.

Diasorin SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (MIL:DIA) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

DIAm:UK 0GZX:UK 34D:Germany DIAS:Austria

Address

Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040

Website

https://www.diasoringroup.com

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).